Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer

Annals of Oncology

Volumn 15, Issue 11, 2004, Pages 1613-1621

  Abratt, R P ^a,j   Brune, D ^b   Dimopoulos, M A ^c   Kliment, J ^d   Breza, J ^e   Selvaggi, F P ^f   Beuzeboc, P ^g   Demkow, T ^h   Oudard, S ⁱ  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b CENTRE FRANÇOIS BACLESSE   (France)

^c ALEXANDRA HOSPITAL   (Greece)

^d Je Senius School of Medicine   (Slovakia)

^e Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^f Ospedale Consorziale Policlinico   (Italy)

^g INSTITUT CURIE   (France)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j UNIVERSITY OF CAPE TOWN   (South Africa)

more..

Author keywords

Hormone therapy; Hormone refractory prostate cancer; Randomised phase III clinical trial; Vinorelbine

Indexed keywords

ALKALINE PHOSPHATASE; AMINOGLUTETHIMIDE; ANALGESIC AGENT; BICALUTAMIDE; CORTICOSTEROID; DOCETAXEL; EPOTHILONE B; ESTRAMUSTINE; FLUTAMIDE; GONADORELIN AGONIST; HEMOGLOBIN; HYDROCORTISONE; MITOXANTRONE; MORPHINE; NAVELBINE; NILUTAMIDE; OPIATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER HORMONE THERAPY; CANCER PAIN; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FATIGUE; HUMAN; HYPOTHESIS; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HORMONES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUTROPENIA; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 9444227104     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh429     Document Type: Article

References (29)

1. Scher H, Steineck G, Kelly WK. Hormone-refractory prostate cancer: refining the concept. Urology 1995; 46: 142-148.
2. Rago R. Management of hormone-sensitive and hormone refractory metastatic prostate cancer. Cancer Control 1998; 5: 513-521.
3. Tannock I, Osoba D, Stockler M et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996; 14: 1756-1764.
4. Culine S, Droz JP. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? Ann Oncol 2000; 11: 1523-1530.
5. Fields-Jones S, Koletsky A, Wilding G et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol 1999; 10: 1307-1310.
6. Oudard S, Cary A, Humblet Y et al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol 2001; 12: 847-852.
7. Morant RH, Schmitz SF, Bernhard J et al. Vinorelbine in androgen-independent metastatic prostate carcinoma-a phase II study. Eur J Cancer 2002; 38: 1626-1632.
8. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72.
9. Vogel C, O'Rourke M, Winer E et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999; 10: 397-402.
10. Buccheri G, Ferrigno D. Vinorelbine in elderly patients with inoperable non-small cell lung carcinoma. Cancer 2000; 88: 2677-2685.
11. Bubley G, Carducci M, Dahut W et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 1999; 17: 2506-2513.
12. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
13. World Health Organisation. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organisation 1979.
14. Scher H, Kelly K, Zhang ZF et al. Post-therapy serum prostate specific antigen level and survival in patients with androgen-independent prostate cancer. J Nal Cancer Inst 1999; 91: 244-251.
15. Dowling AJ, Czaykowski PM, Krahn MD, et al. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 2000; 163: 1481-1485.
16. Laudis J, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
17. Kantoff P, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 3461-3467.
18. Small E, Meyer M, Marshall E et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000; 18: 1440-1450.
19. Havlin K, Trump D. Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancer. Cancer Treat Res 1988; 39: 83-96.
20. Kruit W, Stoter G, Klijn J et al. The efficacy of endocrine combination therapy with aminoglutethimide and hydrocortisone in metastatic prostatic cancer refractory to standard endocrine therapies. Eur J Cancer 2001; 37: (Abstr 804).
21. Petrylak DP, Macarthur RB, O'Connor J et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17: 958-967.
22. Oudard S, Banu E, Vannetzel JM et al. Results of a phase II randomized trial of docetaxel (D), estramustine (E) and prednisone (P) - two schedules - versus mitoxantrone (M) and prednisone (P) in patients with hormone-refractory prostate cancer (HRPC). Ann Oncol 2002; 13 (Suppl 5): 90 (Abstr 3250).
23. Sinibaldi V, Carducci MA, Moore-Cooper S et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen-independent prostate carcinoma. Cancer 2002; 94: 1457-1465.
24. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 2509-2516.
25. Petrylak DP, Tangen C, Hussain M et al. Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol 2004; 23: 2 (Abstr 2).
26. Eisenberger MA, De Wit R, Berry W et al. A multicenter phase III comparison of docetaxel (D)+prednisone (P) and mitoxantrone (MTZ)+P in patients with hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2004; 23: 2 (Abstr 3).
27. Goodin S, Kane MP, Rubin EH et al. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004; 22: 2015-2025.
28. Jassem J, Ramlau E, Karnicka-Modkowska H et al. A multicenter randomised phase II study of oral versus intravenous vinorelbine in advanced non-small cell lung cancer. Ann Oncol 2001; 12: 1375-1381.
29. Freyer G, Delozier T, Lichinister M et al. Phase II study of oral vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35-40.